Aerie Pharmaceuticals reported $119.66M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Aerie Pharmaceuticals AERI:US $ 119.66M 4.37M
Alimera Sciences ALIM:US $ 25.43M 8.43M
Amarin AMRN:US $ 361.57M 61M
Bluebird Bio BLUE:US $ 148.86M 5.97M
Cara Therapeutics CARA:US $ 21.17M 2.87M
Coherus Biosciences CHRS:US $ 140.75M 12.99M
Endo International Ordinary Shares ENDP:US $ 1181.67M 194.47M
Horizon Pharma HZNP:US $ 791.06M 34.12M
Insmed INSM:US $ 113.82M 11.43M
JAZZ PHA JAZZ:US $ 705.44M 31.97M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Novartis NOVN:VX SF 27646M 2161M
Ophthotech OPHT:US $ 26.48M 7.31M
Pacira Pharmaceuticals PCRX:US $ 133.18M 171.89M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Revance Therapeutics RVNC:US $ 77.23M 6.16M
Supernus Pharmaceuticals SUPN:US $ 735.54M 450.98M
Teva Pharmaceutical Industries TEVA:US $ 10996M 617M
Valeant Pharmaceuticals VRX:CN $ 6432.14M 1658.14M
Zoetis ZTS:US $ 3051M 17M